

Date: August 01, 2024

Place: Chennai

Ref: SHAI/B & S/SE/81/2024-25

To,
The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street
Maharashtra, India.
Scrip Code: 543412

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot C/1,
G Block, Bandra-Kurla Complex
Maharashtra, India.
Symbol: STARHEALTH

Dear Sir/ Madam,

Newspaper Advertisement – Financial Results for Q1 FY 2025

Further to our letter ref SHAI/B & S/SE/76/2024-25 dated July 30, 2024 regarding outcome of Board Meeting and in compliance with Regulation 47 and 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a copy of the extract of the unaudited standalone financial results for Q1 FY2025 published in Business Standard (English Edition) and Dinamani (Tamil Edition) for your kind information and records.

The above information is also hosted on the Company's website at www.starhealth.in

Thanking you,

For Star Health and Allied Insurance Company Limited

Jayashree Sethuraman
Company Secretary & Compliance Officer

Encl: as above

Copy to:
IDBI Trusteeship Services Limited,
Asian Building, Ground floor,
Ballard Estate, Mumbai-400 001,
Maharashtra, India.



UGRO CAPITAL LIMITED

CIN : L67120MH1993PLC070739

Regd. Office: Equinox Business Park, Tower 3, 4th Floor, LBS Road, Kurla (West), Mumbai - 400070
Telephone: +91 22 41821600 E-mail: info@ugrocapital.com Website: www.ugrocapital.com

Statement of Unaudited Financial Results for the Quarter ended June 30, 2024

Sr. No.	Particulars	Quarter ended		Year ended March 31, 2024
		June 30, 2024		
		Reviewed	Reviewed	
1	Total income from operations (including Other Income)	30,157.88	21,834.90	1,08,168.12
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items #)	4,282.72	3,564.25	17,876.25
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items #)	4,282.72	3,564.25	17,876.25
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	3,035.59	2,523.59	11,934.48
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	3,014.60	2,079.91	11,384.95
6	Paid up Equity Share Capital	9,165.72	9,119.51	9,159.16
7	Reserves (excluding Revaluation Reserve)	1,82,550.53	1,24,614.47	1,34,677.01
8	Securities Premium Account	1,07,014.06	1,06,331.27	1,06,914.77
9	Net worth	1,91,716.25	1,33,733.99	1,43,836.17
10	Paid up Debt Capital/ Outstanding Debt	4,52,914.61	3,34,227.25	4,65,324.52
11	Outstanding Redeemable Preference Shares	Nil	Nil	Nil
12	Debt Equity Ratio	2.36	2.50	3.23
13	Earnings Per Share (Face Value of ₹ 10/- each) (*Not Annualised)			
	Basic	3.31*	3.06*	13.39
	Diluted	3.22*	3.04*	13.20
14	Capital Redemption Reserve	NA	NA	NA
15	Debtenture Redemption Reserve	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA

- Exceptional items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules.

Notes:

- The above is an extract of the detailed format of Quarterly/Year Ended Financial Results filed with the Stock Exchanges under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed financial results and this extract were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 31st July, 2024. The full format of the Quarterly and Year Ended Financial Results is available on the website of the Company i.e. www.ugrocapital.com and on the websites of the Stock Exchanges i.e. BSE Ltd. (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com).
- For the items referred to in the sub-clauses of the Regulation 52 (4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the pertinent disclosures have been made to the BSE Ltd. and National Stock Exchange of India Limited and can be accessed on www.bseindia.com and www.nseindia.com respectively
- Previous period/year figures have been regrouped / rearranged wherever necessary, to conform with the current period presentation.

For UGRO Capital Limited

Place: Mumbai
Date: 31st July, 2024

Sd/-
Shachindra Nath
Vice Chairman & Managing Director



Oswal Greentech Limited

CIN: L24112PB1981PLC031099

Corporate Office : 7th Floor, Antriksh Bhawan, 22, Kasturba Gandhi Marg, New Delhi-110001

Extract of the Unaudited Standalone Financial Results for the Quarter ended 30th June, 2024

(Amount in ₹ Lakh)

Particulars	Standalone			
	Quarter Ended		Year Ended	
	30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)
Total Income from Operations	1,584.63	2,545.01	693.22	5,560.09
Net Profit/(Loss) for the period/year (before tax)	554.51	477.72	1,401.89	1,052.67
Net Profit/(Loss) for the period/year after tax	467.31	334.48	900.79	637.19
Total Comprehensive Income for the period/year [comprising profit/(loss) for the period/year (after tax) and Other comprehensive income (after tax)]	473.39	358.85	900.86	661.63
Paid up Equity Share Capital (Face Value of ₹10/- each)	25,680.92	25,680.92	25,680.92	25,680.92
Other equity (excluding revaluation reserves) as shown in the Audited Balance Sheet	-	-	-	2,23,262.50
Basic and Diluted Earnings per share (Face Value of ₹10/- each)	0.18	0.13	0.35	0.25

Note:-The above is an extract of the detailed format of the Quarterly Standalone Unaudited Financial Results filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. The full format of the Financial results are available on the stock exchange website www.bseindia.com and www.nseindia.com and also on the Company's website www.oswalgreens.com.

For Oswal Greentech Limited

Sd/-
Anil Kumar Bhalla
CEO and Managing Director

Date: 31.07.2024
Place: New Delhi

Regd. Office : Near Jain Colony, Vijay Inder Nagar, Daba Road, Ludhiana-141 003 (Punjab)
Contact: 0161-2544238; website: www.oswalgreens.com; Email ID: oswal@oswalgreens.com

Balaxi Pharmaceuticals Limited

Registered Office: 3rd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

NOTICE OF THE 81st ANNUAL GENERAL MEETING AND REMOTE E-VOTING INFORMATION

Notice is hereby given that the 81st Annual General Meeting ("AGM") of the Members of Balaxi Pharmaceuticals Limited ("the Company") is scheduled to be held on Friday, August 23, 2024 at 11:30 a.m. (IST) through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as set out in the Notice of AGM in compliance with the applicable provisions of the Companies Act, 2013 and the rules made thereunder read with General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2021 dated May 5, 2020, 02/2021 dated January 13, 2021, 19/2021 dated December 8, 2021, 21/2021 dated December 14, 2021, 2/2022 dated May 5, 2022 and 10/2022 dated December 28, 2022 (collectively the "MCA Circulars") and Circular No. SEBI/HO/CFD/PUD/3/P/2023/023/4 dated January 5, 2023 and October 7, 2023 issued by Securities and Exchange Board of India.

In compliance with the above mentioned circulars, Notice of the AGM along with the Annual Report 2023-24 were sent through electronic mode only on Wednesday, July 31, 2024. To all those Members whose email addresses are registered with the Company Registrar and Transfer Agent/ Depository Participants/ Depositories, Members may note that the Notice and Annual Report 2023-24 are also available on the Company's website www.balaxipharma.in, website of the Stock Exchange i.e., National Stock Exchange of India Limited (www.nseindia.com), and on the website of National Securities Depository Limited (www.nsdl.com). The Company shall send physical copy of the Annual Report 2023-24 to the members who specifically request for the same by sending an email at secretary@balaxi.in.

Instructions for Remote e-Voting:
In compliance with Section 108 of the Act read with the corresponding rules, Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of SEBI circular, SEBI/HO/CFD/CMDR/CIR/P/2020/242 dated December 9, 2020, the Company is providing remote e-voting facility to its members, to enable them to cast their votes electronically through the facility provided by National Securities Depository Limited.

- Members who have cast their votes by remote e-voting prior to the AGM shall not be entitled to cast their votes again.
- Members holding shares either in physical or dematerialized form, as on cut-off date, i.e., Friday, August 16, 2024, may cast their votes electronically through remote e-voting before the AGM or after the AGM. The voting rights of members shall be proportional to their share of the paid-up equity share capital of the Company as on the cut-off date, i.e., Friday, August 16, 2024.
- Any person, who becomes a Member of the Company after dispatch of the Notice of AGM and held shares as on Friday, August 16, 2024 ("cut-off date") may obtain the login ID and password by sending an email to the RTA at info@national securities depository limited by mentioning their Folio No./DP ID and Client ID No. However, if you are already registered with NSDL for e-voting then you can use your existing user ID and password for casting your vote. If you forget your password, you can reset your password by using "Forgot User Details/Password" option available on www.evoting.nsdl.com.
- Only those persons whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date i.e., Friday, August 16, 2024 shall be entitled to avail the facility of remote e-voting before the AGM or e-voting during the AGM.

If you have any queries or issues regarding attending AGM & e-Voting of the Members on the NSDL e-Voting System, you can write an email to evoting@nsdl.com or contact at toll free no. 022-4886 7000.

All grievances connected with the facility for electronic means may be addressed to Mr. Swapneel Pujari, Manager, (NSDL) National Securities Depository Limited at evoting@nsdl.com or call at toll free no. 022-4886 7000.

Members who have not registered their e-mail address in the same in respect of shares held in electronic form with the Depository through their Depository Participant(s) and in respect of shares held in physical form by writing to the Company's RTA, Aarthe Consultants Private Limited, T-2/85, Domalguda, Hyderabad-500 028. E-mail: info@national securities depository limited.

Place: Hyderabad
Date: July 31, 2024

For Balaxi Pharmaceuticals Limited
Sd/-
Mahesh Inani
(Company Secretary and Compliance Officer)
Membership No.: A3757



The Phoenix Mills Limited

Registered Office : 462, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Tel : (022) 43339999 E-mail : investorrelations@phoenixmills.com Website : www.thephoenixmills.com
CIN - L17100MH1905PLC000200

I EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

Sl. No.	Particulars	(Rs. in Lakhs except per share data)		
		Quarter Ended June 30, 2024		Quarter Ended June 30, 2023
		Unaudited	Audited	
1	Total Income from Operations	90,414.05	3,97,768.75	81,062.98
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	38,868.79	1,64,292.32	36,267.85
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	38,817.79	1,64,292.32	36,267.85
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	31,344.11	1,32,632.12	28,970.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	37,750.14	1,38,569.65	31,927.37
6	Equity Share Capital (Face Value of the share - Rs. 2/- each)	3,574.50	3,573.94	3,572.58
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year		9,42,197.16	
8	Earnings Per Share before extraordinary items (of Rs.2/- each) (for continuing and discontinued operations) -			
	Basic :	13.01	61.36	13.46
	Diluted:	13.00	61.31	13.45
	Earnings Per Share after extraordinary items (of Rs.2/- each) (for continuing and discontinued operations) -			
	Basic :	13.01	61.36	13.46
	Diluted:	13.00	61.31	13.45

II EXTRACT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

Sl. No.	Particulars	(Rs. in Lakhs)		
		Quarter Ended June 30, 2024		Quarter Ended June 30, 2023
		Unaudited	Audited	
1	Turnover	11,823.21	46,571.33	11,786.89
2	Profit before tax	10,554.38	32,122.89	6,377.20
3	Profit after tax	9,600.26	28,021.27	5,118.36

Notes:

- The above Financial Results of The Phoenix Mills Limited ("the Company") for the quarter ended June 30, 2024 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on July 31, 2024.
- During the quarter ended June 30, 2024 the paid up equity share capital stands increased by ₹ 0.55 lakhs - (27.812 equity shares of ₹ 2 each) pursuant to the allotment of equity shares on exercise of options by eligible employees, under ESOP schemes 2007 and 2018.
- Based on the results & the financial information regularly reviewed by chief operating decision maker for making decisions about the resource allocation & performance assessment, the group has on consolidated basis identified three reportable segments viz Property & related services, Hospitality services and Residential Business as per Ind AS 108.
- Exceptional item represents tax on gain on account of sale of undivided share in land and applicable Development Potential by the Company to its subsidiary, Pluotrac Commercial Real Estate Private Limited amounting ₹ 51 lakhs.
- The Board of Directors at its meeting held on July 31, 2024 have recommended issuance of 1 bonus share on 1 fully paid-up Equity Share having face value of ₹ 2/- each, subject to approval of the shareholders of the Company.
- Previous period's / year's figures have been regrouped and rearranged wherever necessary to make them comparable with current period.
- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the Company at www.thephoenixmills.com/investors.

For The Phoenix Mills Limited

Date: July 31, 2024
Place: Mumbai

Sd/-
Shishir Shrivastava
Managing Director
DIN: 01266095



STAR HEALTH AND ALLIED INSURANCE COMPANY LIMITED

Registration No. and Date of Registration with the IRDAI : 129/16.03.2006

CIN: L66010TN2005PLC056649

STATEMENTS OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2024

Sr. No.	Particulars	Three Months Ended			Year Ended
		June 30, 2024		March 31, 2024	
		Unaudited	Unaudited		
1	Total Income from Operations (Note 1)	347,592	294,863	1,525,445	
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Item)	42,617	38,435	112,885	
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Item)	42,617	38,435	112,885	
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Item)	31,893	28,785	84,501	
5	Total Comprehensive Income for the period (Comprising Profit / (loss) for the period (after tax) and Other Comprehensive Income (after tax))	NA	NA	NA	
6	Paid up Equity Capital	58,547	58,198	58,528	
7	Reserves (excluding Revaluation Reserve)	3,232	-	-	
8	Securities Premium Account	604,337	598,570	604,056	
9	Net Worth	666,117	572,393	633,924	
10	Paid up Debt Capital	47,000	47,000	47,000	
11	Debtenture Redemption Reserves	-	-	-	
12	Earnings per share (face value of ₹ 10/- each)				
	1. Basic (in ₹)	5.45	4.95	14.48	
	2. Diluted (in ₹)	5.37	4.83	14.19	
13	Debt Equity Ratio (No. of times)	0.06	0.07	0.07	
14	Debt Service Coverage Ratio (No. of times)	42.68	38.49	28.39	
15	Interest Service Coverage Ratio (No. of times)	42.68	38.49	28.39	

- Notes:**
- Total Income from Operations represents Gross Written Premium (GWP).
 - The Indian Accounting Standards (IND AS) are currently not applicable to Insurance Companies in India.
 - The above results for the quarter ended June 30, 2024 were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on July 30, 2024 and the Joint Statutory Auditors of the Company have reviewed the same.
 - The above is an extract of the detailed format of quarterly and year to date Financial results filed with the Stock Exchange under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure requirements) regulations, 2015. The full format of quarterly and year to date Financial results are available on the website of Stock Exchanges (www.nseindia.com) and (www.bseindia.com) and the Company (www.starhealth.in).

For And On Behalf of Board of Directors

Place: Chennai
Date: July 30, 2024

Sd/-
Anand Roy
Managing Director & Chief Executive Officer
DIN: 08602245

